Understanding the Investigation into Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is now under the scrutiny of Bragar Eagel & Squire, P.C., a law firm known for defending shareholder rights. The firm has initiated an investigation focusing on potential claims related to the company’s operations and disclosures that may have affected long-term stockholders. If you've invested in Capricor, it's crucial to stay informed about these developments.
The Core Issues Surrounding Capricor
The investigation stems from a class action complaint filed against Capricor on July 17. It raises significant concerns about whether the company's board of directors has acted in the best interests of its shareholders. The core of the allegations involves statements made regarding Capricor's lead therapy candidate, deramiocel, intended for treating cardiomyopathy linked to Duchenne muscular dystrophy (DMD).
Misleading Information and Its Consequences
Investors were reportedly provided with positive updates about deramiocel, including expectations for obtaining a Biologics License Application (BLA) from the FDA. However, the complaint alleges that the company concealed critical data from its Phase 2 clinical trials, specifically concerning the safety and effectiveness of the treatment over its four-year study.
Stock Price Reaction to News
On July 11, Capricor announced that it had received a Complete Response Letter (CRL) from the FDA, denying the proposed BLA. The letter noted that the company failed to meet the necessary requirements for showing substantial evidence of efficacy, leading to a decline in the stock price from $11.40 to $7.64 within a day. Such a significant drop raises questions about the management's duty to its investors.
Steps for Affected Investors
If you are a long-term investor in Capricor, reaching out to a legal expert to discuss your rights may be prudent. Bragar Eagel & Squire provides avenues for shareholders to learn more about their rights and explore potential claims as they pertain to this situation.
Contacting Legal Experts
Investors can get in touch directly with Brandon Walker or Marion Passmore at Bragar Eagel & Squire by calling (212) 355-4648. They are available to share insights and explore options for those affected by the recent developments.
More About Bragar Eagel & Squire
Bragar Eagel & Squire, P.C. is a well-respected law firm recognized for advocating on behalf of private and institutional investors. They specialize in handling complex litigation, including securities and derivative cases, across multiple jurisdictions.
Stay Informed About Capricor
As this investigation continues, it's essential for investors to remain updated about any new developments. Being informed can help you make decisions about your investments and prepare for any potential changes in the market.
Frequently Asked Questions
What is happening with Capricor Therapeutics?
Capricor is currently under investigation for potential shareholder rights violations due to allegations of providing misleading information.
How can I find out more about this investigation?
You can contact Bragar Eagel & Squire directly for details regarding the investigation and your rights as an investor.
What does the stock price drop indicate?
The sharp decline in stock price reflects investor concerns following the FDA's rejection of Capricor's drug application.
Who should I contact if I am affected?
Investors are encouraged to reach out to Brandon Walker or Marion Passmore at Bragar Eagel & Squire for assistance.
What does Bragar Eagel & Squire do?
The firm specializes in representing investors in complex litigation, including matters related to securities fraud and shareholder rights.
